Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has been assigned an average rating of "Buy" from the seven ratings firms that are presently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $11.36.

Several brokerages have recently weighed in on VOR. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Vor Biopharma in a research report on Monday, December 9th. HC Wainwright restated a "buy" rating and issued a $17.50 target price on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird dropped their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a research report on Friday, November 8th. Finally, JMP Securities reissued a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Vor Biopharma Price Performance

Shares of VOR traded down $0.09 during midday trading on Wednesday, reaching $1.41. The stock had a trading volume of 467,818 shares, compared to its average volume of 510,213. The company has a market cap of $96.83 million, a price-to-earnings ratio of -0.85 and a beta of -0.45. The company's fifty day simple moving average is $1.21 and its two-hundred day simple moving average is $0.97. Vor Biopharma has a 1-year low of $0.63 and a 1-year high of $2.43.

Vor Biopharma (NYSE:VOR - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.40). On average, sell-side analysts forecast that Vor Biopharma will post -1.42 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of VOR. Cubist Systematic Strategies LLC acquired a new stake in shares of Vor Biopharma during the second quarter worth about $53,000. Rosalind Advisors Inc. purchased a new stake in Vor Biopharma during the 3rd quarter valued at approximately $54,000. Exchange Traded Concepts LLC lifted its position in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock worth $116,000 after acquiring an additional 48,017 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Vor Biopharma by 48.0% in the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company's stock valued at $495,000 after purchasing an additional 160,642 shares during the last quarter. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.